ArticleClinical cancer research : an official journal of the American Association for Cancer Research2019
Functional Silencing of
Open access · bronzeAbstract read
In one paragraph
Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed
3.3field-weighted citation impact, top 7% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 49 citations in OpenAlex.
- Causal links of 233 metabolic markers to benign prostatic hyperplasia: Mendelian randomization and RNA-sequencing insights.Journal of the Chinese Medical Association : JCMA · 2026Article
- Analysis of the transcriptomic and metabolomic landscape of prostate cancer with different anatomical origins using snFLARE-seq and mxFRIZNGRND.Nature communications · 2026Article
- Reduced UPF1 levels in senescence impair nonsense-mediated mRNA decay.Communications biology · 2025Article
- Decoding the enigmatic estrogen paradox in pulmonary hypertension: delving into estrogen metabolites and metabolic enzymes.Cellular & molecular biology letters · 2024Review
- Targeting SRSF10 might inhibit M2 macrophage polarization and potentiate anti-PD-1 therapy in hepatocellular carcinoma.Cancer communications (London, England) · 2024Article
- Characterization and Functional Analysis of the 17-Beta Hydroxysteroid Dehydrogenase 2 (International journal of molecular sciences · 2024Article
- Whole transcriptome landscape in HAPE under the stress of environment at high altitudes: new insights into the mechanisms of hypobaric hypoxia tolerance.Frontiers in immunology · 2024Article
- Active DHEA uptake in the prostate gland correlates with aggressive prostate cancer.The Journal of clinical investigation · 2023Article
- Whole-Genome Resequencing Reveals Selection Signal Related to Sheep Wool Fineness.Animals : an open access journal from MDPI · 2023Article
- Revealing metastatic castration-resistant prostate cancer master regulator through lncRNAs-centered regulatory network.Cancer medicine · 2023Article
- Towards understandings of serine/arginine-rich splicing factors.Acta pharmaceutica Sinica. B · 2023Review
- Abnormal DNA methylation within genes of the steroidogenesis pathway two years after paediatric critical illness and association with stunted growth in height further in time.Clinical epigenetics · 2023Article
- Deregulated microRNAs Involved in Prostate Cancer Aggressiveness and Treatment Resistance Mechanisms.Cancers · 2023Review
- The role of 11-oxygenated androgens in prostate cancer.Endocrine oncology (Bristol, England) · 2023Review
- CPEB2 m6A methylation regulates blood-tumor barrier permeability by regulating splicing factor SRSF5 stability.Communications biology · 2022Article
- A long non-coding RNA as a direct vitamin D target transcribed from the antisense strand of the human HSD17B2 locus.Bioscience reports · 2022Article
- Management of prostate cancer by targeting 3βHSD1 after enzalutamide and abiraterone treatment.Cell reports. Medicine · 2022Article
- Identification of Metabolism-Related Gene-Based Subgroup in Prostate Cancer.Frontiers in oncology · 2022Article
- Article
- The Histone Variant MacroH2A1 Impacts Circadian Gene Expression and Cell Phenotype in an In Vitro Model of Hepatocellular Carcinoma.Biomedicines · 2021Article
Corrections and comments
- Commented on by
Authors and funding
17 authors at 4 institutions in 2 countries.
Xiaomei Gao *State Key Laboratory of Cell Biology, CAS Center for Excellence in Molecular Cell Science, Shanghai Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences, University of Chinese Academy of Sciences, Shanghai, P.R. China.
Charles Dai *Department of Cancer Biology, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio.
Shengsong Huang *Department of Urology, Tongji Hospital, Tongji University School of Medicine, Shanghai, P.R. China.
Jingjie Tang *State Key Laboratory of Cell Biology, CAS Center for Excellence in Molecular Cell Science, Shanghai Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences, University of Chinese Academy of Sciences, Shanghai, P.R. China.
Guoyuan ChenState Key Laboratory of Cell Biology, CAS Center for Excellence in Molecular Cell Science, Shanghai Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences, University of Chinese Academy of Sciences, Shanghai, P.R. China.
Jianneng LiDepartment of Cancer Biology, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio.
Ziqi ZhuDepartment of Cancer Biology, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio.
Xuyou ZhuDepartment of Pathology, Tongji Hospital, Tongji University School of Medicine, Shanghai, P.R. China.
Shuirong ZhouState Key Laboratory of Cell Biology, CAS Center for Excellence in Molecular Cell Science, Shanghai Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences, University of Chinese Academy of Sciences, Shanghai, P.R. China.
Yuanyuan GaoState Key Laboratory of Cell Biology, CAS Center for Excellence in Molecular Cell Science, Shanghai Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences, University of Chinese Academy of Sciences, Shanghai, P.R. China.
Zemin HouState Key Laboratory of Cell Biology, CAS Center for Excellence in Molecular Cell Science, Shanghai Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences, University of Chinese Academy of Sciences, Shanghai, P.R. China.
Zijun FangState Key Laboratory of Cell Biology, CAS Center for Excellence in Molecular Cell Science, Shanghai Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences, University of Chinese Academy of Sciences, Shanghai, P.R. China.
Chengdang XuDepartment of Urology, Tongji Hospital, Tongji University School of Medicine, Shanghai, P.R. China.
Jianyang WangState Key Laboratory of Cell Biology, CAS Center for Excellence in Molecular Cell Science, Shanghai Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences, University of Chinese Academy of Sciences, Shanghai, P.R. China.
Denglong WuDepartment of Urology, Tongji Hospital, Tongji University School of Medicine, Shanghai, P.R. China. zhenfei.li@sibcb.ac.cn sharifn@ccf.org Wudenglong2009@tongji.edu.cn.
Nima SharifiDepartment of Cancer Biology, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio. zhenfei.li@sibcb.ac.cn sharifn@ccf.org Wudenglong2009@tongji.edu.cn.
Zhenfei LiState Key Laboratory of Cell Biology, CAS Center for Excellence in Molecular Cell Science, Shanghai Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences, University of Chinese Academy of Sciences, Shanghai, P.R. China. zhenfei.li@sibcb.ac.cn sharifn@ccf.org Wudenglong2009@tongji.edu.cn.
Center for Excellence in Molecular Cell Science · CNTongji University · CNCleveland Clinic Lerner College of Medicine · USCleveland Clinic · US
Funding
Elucidating a novel molecular biomarker for castration-resistant prostate cancerR01CA172382 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI Nima Sharifi · 2012 to 2026
$5.2MCompensatory steroidogenesis mechanisms in castration-resistant prostate cancerR01CA190289 · NCI · CLEVELAND CLINIC LERNER COM-CWRU · PI SHARIFI, NIMA · 2015 to 2019
$2.1MCooperative steroidogenic inhibition for treatment of advanced prostate cancerR01CA168899 · NCI · CLEVELAND CLINIC LERNER COM-CWRU · PI SHARIFI, NIMA · 2013 to 2017
$1.6MNCI NIH HHS R01 CA168899NCI NIH HHS R01 CA172382NCI NIH HHS R01 CA190289
Abstract
purposeSteroidogenic enzymes are essential for prostate cancer development. Enzymes inactivating potent androgens were not investigated thoroughly, which leads to limited interference strategies for prostate cancer therapy. Here we characterized the clinical relevance, significance, and regulation mechanism of enzyme EXPERIMENTAL
design
results
conclusionsOur findings provide evidence of the clinical relevance, significance, and regulation of
Indexed as
AnimalsCarcinogenesisCell Line, TumorCell ProliferationDisease ProgressionEstradiol DehydrogenasesGene Expression Regulation, NeoplasticGene SilencingHeterograftsHumansMaleMiceProstatic NeoplasmsReceptors, AndrogenEstradiol DehydrogenasesHSD17B2 protein, humanReceptors, Androgen
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.